Bluejay Diagnostics, Inc. (BJDX)
NASDAQ: BJDX · Real-Time Price · USD
1.830
-0.160 (-8.04%)
At close: Jun 10, 2025, 4:00 PM
1.790
-0.040 (-2.19%)
Pre-market: Jun 11, 2025, 4:37 AM EDT
Bluejay Diagnostics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
7
Market Cap
2.73M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
BJDX News
- 7 days ago - Bluejay Diagnostics Provides Mid-Year Business and Corporate Update - GlobeNewsWire
- 2 months ago - Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting - GlobeNewsWire
- 2 months ago - Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds - GlobeNewsWire
- 7 months ago - Bluejay Diagnostics Announces Reverse Stock Split - GlobeNewsWire
- 1 year ago - Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering - GlobeNewsWire
- 1 year ago - SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients - GlobeNewsWire
- 1 year ago - Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering - GlobeNewsWire
- 1 year ago - Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering - GlobeNewsWire